Listing 3.03 Asthma in 2026: How FEV1 at or Below Table VI-A or VI-B, or Three Hospitalizations of 48 Hours Each at Least 30 Days Apart Within 12 Months Despite Biologic Therapy Meets the Rule

Published July 7, 2026 by Anthony Albert, Benefits Research Director, Disability Exchange. Reading time about 22 minutes.

About 25 million Americans have asthma. Roughly 5 to 10 percent of adult asthmatics have severe asthma, defined by GINA as requiring high-dose inhaled corticosteroids plus a second controller to prevent uncontrolled symptoms, or remaining uncontrolled despite that regimen. Of that group, a portion becomes so functionally limited by exacerbations and steroid side effects that they can't hold a job. That's the pool of people who file SSDI for asthma. Most get denied on the first pass. Not because they're not sick, but because the file doesn't map to Listing 3.03. This article walks the exact rule, the two paths that meet it, and how to file a winnable claim.

The Verbatim Rule in Listing 3.03

Section 3.00 of the blue book covers respiratory disorders. Listing 3.03 for asthma has two independent paths. Meeting either one is enough.

Path A is a spirometry number. Path B is a hospitalization pattern. They're independent. You don't need both. Most people file under Path B because Path A requires a very low FEV1 that not everyone with severe asthma reaches on the day of testing.

Path A: FEV1 Below Table VI-A

Table VI-A gives the maximum FEV1 for adults by height. FEV1 is measured post-bronchodilator per SSA's spirometry protocol in section 3.00E. Some example thresholds from Table VI-A for adults 20 years and older:

These are the same thresholds SSA uses for COPD under Listing 3.02(A). The rationale: if lung function is impaired to this level from any cause, work sustainability is unlikely.

Spirometry protocol per 3.00E

The FEV1 has to be done to SSA standards. Section 3.00E requires:

• Best of three acceptable spirometry maneuvers, each with a good start of test, no cough during the first second, and consistent effort
• Post-bronchodilator FEV1 measured 10 to 30 minutes after inhaled beta-2 agonist (usually albuterol 4 puffs or nebulized 2.5 mg)
• Volume-time and flow-volume curves included with the report
• Height measured in stocking feet
• Testing done during a period of clinical stability, not during an acute exacerbation
• Standing height, gender, age, and race documented on the report

DDS routinely rejects spirometry that doesn't include the flow-volume loops or that shows sub-maximal effort. If your pulmonologist's report is missing pieces, the adjudicator will schedule a consultative exam and repeat testing, adding months to the process.

The problem with Path A for many asthmatics

Asthma is variable by nature. A person with severe asthma might have FEV1 of 32 percent predicted during an exacerbation and 68 percent predicted between exacerbations. If SSA tests them on a good day, they're above threshold. If tested on a bad day, they're below. That's why Path B (the hospitalization path) exists.

Path B: Three Hospitalizations of 48 Hours, 30 Days Apart, in 12 Months

This is where most severe asthma claims live. The math is strict.

What counts as a hospitalization

Admission to an inpatient bed for at least 48 continuous hours. Time in the emergency department immediately before admission counts toward the 48 hours if it flowed directly into inpatient status without discharge in between. So if you spent 12 hours in the ER, then were admitted to a floor bed for 40 hours, that's 52 hours total and counts.

What doesn't count as a hospitalization

• ER visit that resulted in discharge home, no matter how long the stay
• Observation status admissions (this is the trickiest area, discussed below)
• Inpatient stays for reasons other than asthma exacerbation or complications
• Overnight monitoring under 48 hours

Observation status vs inpatient status

Some hospitals put asthma patients on "observation" for 24 to 48 hours to avoid inpatient admission billing. Observation stays don't count under Path B unless they were later converted to inpatient status. If your hospital records show observation only, ask the discharge summary to be corrected to inpatient if clinically appropriate. Medicare's Two Midnight Rule and hospital-level utilization review committees make this a documented process, and it can be revisited on medical record request.

The 30-day-apart rule

The 30 day interval is measured from the start date of one hospitalization to the start date of the next. So a hospitalization starting January 5 and one starting February 3 is 29 days apart and doesn't count as separate events under the listing. Move one by a day and they do. This detail sinks many claims where the file has three admissions but two are 28 or 29 days apart.

The 12 month window

All three admissions have to fall within a consecutive 12 month period. A rolling window applies. So admissions in March 2025, September 2025, and February 2026 all fall within a 12 month window starting March 2025 and count. Admissions in January 2024, September 2024, and February 2026 do not (the last is more than 12 months after the first).

Complications

The rule says "exacerbations or complications." Complications include pneumonia treated as inpatient because underlying asthma made the pneumonia severe, mechanical ventilation for status asthmaticus, respiratory failure requiring BiPAP or intubation, or steroid-induced complications requiring admission. All of these count if they're documented as consequences of asthma rather than independent conditions.

Which Asthma Phenotypes Show Up Most in 3.03 Claims

Severe eosinophilic asthma

Blood eosinophil counts above 300 cells/microL. Often on biologics (mepolizumab, benralizumab, reslizumab) with ongoing exacerbations despite therapy. Type 2 high inflammation phenotype. FeNO usually elevated over 25 ppb. These patients frequently meet Path B.

Severe allergic asthma

Total IgE elevated with documented aeroallergen sensitization on skin prick or specific IgE testing. Often on omalizumab (Xolair) with breakthrough exacerbations. Environmental triggers like dust mites, cockroach, mold, or animal dander that can't be avoided in daily living or work settings.

Steroid-dependent asthma

Requires oral corticosteroids more than half the days of the year to maintain baseline function. Chronic prednisone at 5 to 20 mg daily is common. Complications include steroid-induced diabetes, osteoporosis, cataracts, adrenal suppression, and Cushing's features. These secondary conditions can support the asthma claim or be filed separately.

Aspirin-exacerbated respiratory disease (AERD, Samter's triad)

Asthma, nasal polyposis, and NSAID sensitivity. Often severe and difficult to control even on biologics. Chronic sinus disease compounds work limitations.

Occupational asthma

Isocyanates, flour dust, latex, laboratory animal allergens, and other workplace triggers. Even after removal from exposure, some patients don't recover and continue to have exacerbations. Documented via specific challenge testing or serial peak flow monitoring correlated to work exposure.

Biologic Therapy Documentation

SSA doesn't require biologic therapy to meet the listing. But your file is stronger if it shows biologic therapy tried and failed to prevent exacerbations. The FDA-approved biologics for severe asthma in 2026:

For SSDI documentation, include:

• Biologic name, dose, start date, and duration of therapy
• Pre-biologic exacerbation frequency and post-biologic exacerbation frequency (should show ongoing exacerbations if you're filing under Path B)
• Documented reasons for switching biologics if applicable
• Any biologic side effects or adverse events
• Payer approval and refill history to show adherence

What Testing You Actually Need

Complete pulmonary function testing

Spirometry with pre and post bronchodilator FEV1, FVC, FEV1/FVC ratio, plus flow-volume loops. Ideally lung volumes (TLC, RV) by plethysmography to distinguish asthma from restrictive disease. Diffusing capacity (DLCO) is usually normal or elevated in asthma; if it's low, look for other causes.

Bronchodilator response

Increase in FEV1 of 12 percent and 200 mL or more after inhaled beta agonist confirms reversible airflow obstruction (asthma). Fixed obstruction that doesn't reverse points more toward COPD, which is evaluated under 3.02 with the same FEV1 tables.

Bronchoprovocation testing

Methacholine challenge if baseline spirometry is normal but asthma is suspected. PC20 (concentration causing 20 percent FEV1 drop) below 4 mg/mL supports asthma diagnosis. Not required for the listing but useful in atypical cases.

Blood eosinophil count and total IgE

Phenotype markers. Not required for the listing but relevant to biologic selection and inflammation.

FeNO (fractional exhaled nitric oxide)

Above 25 ppb suggests Type 2 inflammation. Useful for biologic selection.

Chest imaging

Chest CT to rule out bronchiectasis, ABPA (allergic bronchopulmonary aspergillosis), tumors, or other causes of the exacerbations. High resolution CT can show air trapping, mucous plugging, or bronchial wall thickening in severe asthma.

Pulmonologist longitudinal notes

At least 12 months of follow-up notes documenting exacerbations, treatment escalation, and functional status. Notes that describe missed work, hospitalizations, ER visits, and functional limits carry more weight than notes that just say "asthma, refills given."

Worked Example 1: Sofia, 42, Severe Eosinophilic Asthma, Cambridge MA

Worked Example 2: Marcus, 55, Steroid-Dependent Asthma, Jacksonville FL

Common Denial Reasons and How to Fix Them

Hospitalizations under 48 hours

Three ER-to-discharge visits, or three 24 hour "obs" stays, don't count. Fix: request medical record review to see whether observation stays should have been inpatient per hospital utilization review criteria. If yes, get the record corrected.

Admissions 28 or 29 days apart

Missing the 30 day rule by 1 to 2 days. Fix: look at the exact admission dates and times. Sometimes there's a nuance (arrival date vs admission date) that shifts the interval. If two admissions are close, count from the earlier one that clearly meets, and hope for a third that pushes total spacing over 30 days apart.

Only 2 admissions in 12 months

Not enough for Path B. Options: wait for a third admission before filing, or file under Path A if FEV1 meets, or file under a residual functional capacity theory with a grid rule at step five.

FEV1 above threshold on the day of testing

Test done on a good day. Fix: repeat spirometry during a bad episode or ask for a consultative exam if funding is available. Also submit peak flow logs showing significant daily variability (over 20 percent morning to evening) as evidence of poorly controlled asthma even when spot FEV1 is above threshold.

Spirometry protocol errors

Missing post-bronchodilator numbers. Missing flow-volume loops. No height documented. Fix: ask your pulmonologist to redo the study to SSA standards per 3.00E, or wait for the DDS consultative exam.

Documentation gaps between exacerbations

File shows three hospitalizations but nothing in between. DDS thinks the asthma might be controlled outside of acute events. Fix: include pulmonology follow-up notes from between admissions showing ongoing symptoms, medication adjustments, and functional limits.

Path C: When Neither A Nor B Works

Some severe asthma claimants don't meet Path A (FEV1 above threshold on testing) or Path B (fewer than three qualifying hospitalizations). They can still win through step five of the sequential evaluation using a residual functional capacity analysis.

The RFC evidence that supports asthma claims:

• Peak flow variability logs showing daily swings of 30 percent or more
• Symptom logs showing multiple weekly rescue inhaler uses despite controller therapy
• Pulmonologist statements about environmental triggers that make workplace exposure infeasible (perfumes, cleaning products, cold air, dust)
• Employer documentation of unscheduled absences due to asthma
• Steroid side effect documentation (fatigue, weight gain, mood changes, sleep disruption) that limits sustained work

Combined with vocational factors (age 50 or over with limited transferable skills), an RFC-based asthma claim can win at hearing under grid rule 202.06 or similar. Read our medical-vocational grid rules guide for the mechanics.

Timing, Waiting Period, and Medicare

SSDI has a 5 month waiting period from established onset date to first payment. For asthma cases meeting Path B, the EOD is usually the first qualifying hospitalization date within the 12 month window. For Path A, the EOD is the date the FEV1 first documented listing-level obstruction with expected 12 month duration.

Medicare kicks in 24 months after SSDI entitlement begins (so 29 months after EOD counting the 5 month waiting period). For severe asthma patients on biologics, that's important. Biologic infusions and injections average $30,000 to $50,000 per year without insurance. Medicare Part B covers most in-office biologics; Part D covers most oral medications. Bridge coverage during the 29 month gap matters for anyone whose biologic isn't affordable out of pocket.

Retroactive back pay caps at 12 months before application. Protective filing date can push that back. See our protective filing and retroactive benefits guide.

Return-to-Work Considerations

SSDI approval isn't a permanent verdict. If your asthma later stabilizes on newer biologics or after removing an environmental trigger, you can attempt return to work through Ticket to Work, Trial Work Period (TWP), and Extended Period of Eligibility (EPE) provisions. In 2026, TWP threshold is $1,110 per month and SGA is $1,620 non-blind or $2,700 blind. See our Trial Work Period and EPE guide.

Frequently Asked Questions

Related Reading

• Listing 3.02 COPD Deep Dive
• Medical-Vocational Grid Rules 2026
• Trial Work Period and EPE 2026
• Section 1619(b) Medicaid State Thresholds
• ALJ Hearing Prep 2026